Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
2025 · The Oncologist · 9 citations
https://doi.org/10.1093/oncolo/oyae360
R
Rajash Pallai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
12
Papers
194
Citations
7
h-index
5
i10-index
Rajash Pallai is an academic researcher. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Colorectal Cancer Treatments and Studies & CAR-T cell therapy research. The author has an h-index of 7, co-authored 11 publications.
Papers by this author
worksEfficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
2025 · International Journal of Clinical Oncology · 1 citations
https://doi.org/10.1007/s10147-025-02852-9
ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01495-2
Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)00791-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat